Abstract | PURPOSE: EXPERIMENTAL DESIGN: RESULTS: ABT-737-treated tumors regressed by 48 hours (P < 0.01) compared with controls, correlating with increased cleaved cytokeratin 18 (P < 0.01; 6 and 24 hours) and increased intact cytokeratin 18 (P < 0.01; 24 hours). Cleaved cytokeratin 18 levels decreased below baseline between 72 and 360 hours for ABT-737-treated and control mice whereas intact cytokeratin 18 decreased below the level of detection at 8 and 15 days in ABT-737-treated mice only. Apoptosis in tumors reflected changes in circulating cytokeratin 18 (cleaved caspase-3, P < 0.05 at 2 hours and P < 0.001 at 6, 12, and 24 hours; caspase-cleaved cytokeratin 18, P < 0.05 at 15 days, for drug treated versus controls). CONCLUSIONS:
|
Authors | Dimitra Micha, Jeff Cummings, Alex Shoemaker, Steven Elmore, Kelly Foster, Martin Greaves, Tim Ward, Saul Rosenberg, Caroline Dive, Kathryn Simpson |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 14
Issue 22
Pg. 7304-10
(Nov 15 2008)
ISSN: 1078-0432 [Print] United States |
PMID | 19010845
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- ABT-737
- Antineoplastic Agents
- Biomarkers, Tumor
- Biphenyl Compounds
- Keratin-18
- Nitrophenols
- Piperazines
- Sulfonamides
- Butylated Hydroxytoluene
- BH 3
- Caspase 3
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use)
- Apoptosis
(drug effects, physiology)
- Biomarkers, Tumor
(blood)
- Biomimetic Materials
(therapeutic use)
- Biphenyl Compounds
(therapeutic use)
- Butylated Hydroxytoluene
(analogs & derivatives, chemistry)
- Caspase 3
(metabolism)
- Cell Line, Tumor
- Enzyme-Linked Immunosorbent Assay
- Humans
- Immunohistochemistry
- Keratin-18
(blood, metabolism)
- Lung Neoplasms
(blood, drug therapy)
- Mice
- Nitrophenols
(therapeutic use)
- Piperazines
(therapeutic use)
- Small Cell Lung Carcinoma
(blood, drug therapy)
- Sulfonamides
(therapeutic use)
- Xenograft Model Antitumor Assays
|